The impact of angiogenesis on the prognosis of advanced renal cell carcinomas.
We studied the relationship between angiogenic factors and clinical responses in advanced renal cell carcinomas (RCCs) and evaluated the angiogenic factors to clarify the potential impact of these factors on the cancer-specific survival. From January 1990 to December 2000, 148 patients underwent a nephrectomy for RCCs at our institution. Of the 32 patients who had distant metastasis, 17 met the histopathologic analysis requirements for an immuno-histochemical investigation. Fifteen of them were administered interferon-gamma and the remaining two patients were added to interferon-alpha and eight of seventeen patients also underwent radiation therapy. Both thymidine phosphorylase (TP) and Factor VIII immunostaining were performed. The overall survival rates at 1, 5 and 10 years were 82.4%, 30% and 30%, respectively. Three of these patients were diagnosed with lung metastasis and a complete response was seen in two, while a partial response was observed in one. In addition another patient who was diagnosed with bone metastasis also showed a partial response (group A). The remaining 13 patients showed progressive disease (group B). Group A had a higher TP-positive ratio (TP-PR) than that of group B. A multivariate analysis of the clinicopathologic data showed that a positive mean vascular area (PMVA) could be an independent factor regarding the potential impact of these factors on a long survival in advanced RCCS. PMVA was thus found to be an independent factor regarding the prognosis with advanced RCCs.
Kawata
Nozomu
N
Department of Urology, Nihon University School of Medicine, Surugadai Nihon University Hospital.
Yagasaki
Hiroki
H
Hirakata
Hitoshi
H
Nagane
Yusuke
Y
Morita
Koutaro
K
Sugimoto
Shuji
S
Igarashi
Takumi
T
Takimoto
Yukie
Y
D000368:Aged; D002292:Carcinoma, Renal Cell / Q000098:blood supply* / Q000401:mortality / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D007371:Interferon-gamma / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000098:blood supply* / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009389:Neovascularization, Pathologic / Q000401:mortality / Q000628:therapy; D009392:Nephrectomy; D011379:Prognosis; D015996:Survival Rate
D016898:Interferon-alpha; D007371:Interferon-gamma